Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + trastuzumab + aromatase inhibitor versus dual-comparator regimens in hormone receptor-positive, HER2-positive metastatic breast cancer
2010-019577-16Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of lapatinib, trastuzumab, letrozole, anastrozole and exemestane in breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Oct 2010; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-019577-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019577-16.